ACCEPT 1/2期试验:西妥昔单抗联合同步调强放疗联合碳离子推量治疗头颈部腺样囊性癌
ACCEPT 1/2期试验(NCT01192087)评估西妥昔单抗联合同步调强放疗联合碳离子推量治疗初诊非转移性头颈部腺样囊性癌的安全性与可行性。3年无病生存率67%,中位总生存54个月;因3级皮炎发生率较高未达到预设可行性标准。
要点
- 3级皮疹17%、放射性皮炎22%,因3级皮炎发生率较高未达预设可行性标准。
- 3年无病生存率67%,中位总生存54个月,5例(22%)野内复发,6例(26%)远处转移。
核心结论
- 该联合方案治疗初诊非转移性头颈部腺样囊性癌的结局令人满意,但因3级放射性皮炎发生率较高未达到预设可行性标准。
- 毒性数据与现有西妥昔单抗联合放疗的数据相当。
研究设计与样本
- ACCEPT为1/2期试验(NCT01192087),评估西妥昔单抗联合同步调强放疗联合碳离子推量治疗初诊非转移性头颈部腺样囊性癌。
- 主要终点为安全性和可行性(基于常见不良事件评价标准≥3级事件定义),次要终点包括局部和远处复发、无病生存及总生存。
主要发现
- 肿瘤最常见于鼻旁窦(30%)、腭部(17%)和鼻咽(17%)。
- 9例(39%)患者接受手术(R1占22%,R2占78%)。
- 中位随访38.5个月,无患者发生4-5级事件;3级皮疹和放射性皮炎发生率分别为17%和22%。
- 2级和3级口腔黏膜炎发生率分别为43%和9%,味觉障碍分别为48%和0%。
- 2-3级吞咽困难发生率为43%(2级)和4%(3级),口干为26%(2级)和0%(3级)。
关键数值与推荐
- 西妥昔单抗负荷剂量400 mg/m2于放疗前一周给予,随后自放疗第一天起每周250 mg/m2。
- 碳离子放疗推量24 Gy(相对生物效应)分8次每日照射,随后调强放疗54 Gy。
- 可行性预设标准基于常见不良事件评价标准≥3级事件,因3级皮炎发生率较高未达到该标准。
临床怎么用
- 该联合方案可用于初诊非转移性头颈部腺样囊性癌,但需关注3级放射性皮炎和皮疹。
- 治疗期间应重点监测皮肤毒性、口腔黏膜炎、吞咽困难和口干。
局限性
- 因3级皮炎发生率较高未达到预设可行性标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The adenoid cystic carcinoma (ACC), Erbitux, and Particle Therapy (ACCEPT) phase 1/2 trial (NCT01192087) evaluated a combined-modality approach (concurrent cetuximab and intensity modulated radiation therapy with carbon ion boost) for newly diagnosed nonmetastatic head and neck ACC. METHODS AND MATERIALS: Twenty-three patients with ACC were enrolled between June 2012 and June 2017 after initial diagnosis or postoperatively. All received a 400 mg/m2 cetuximab loading dose a week before radiation therapy, followed by weekly 250 mg/m2 doses starting on the first day of radiation therapy. The carbon ion radiation therapy boost was 24 Gy (relative biological effectiveness) in 8 daily fractions, followed by intensity modulated radiation therapy (54 Gy). The primary endpoint was safety and feasibility (defined based on Common Terminology Criteria for Adverse Events grade ≥3 events). Secondary endpoints included local and distant relapse, disease-free survival, and overall survival. RESULTS: Disease was most commonly in the paranasal sinuses (30%), palate (17%), and nasopharynx (17%). Nine (39%) patients underwent surgery (R1: 22%, R2: 78%). Median follow-up was 38.5 months. No patients experienced grade 4 to 5 events. Rates of grade 3 rash and radiation dermatitis were 17% and 22%, respectively. Grade 2 and 3 mucositis and dysgeusia occurred in 43% and 48% and in 9% and 0%, respectively. Grade 2 to 3 dysphagia and xerostomia were present in 43% and 4% and in 26% and 0%, respectively. At last follow-up, 5 (22%) patients experienced in-field relapse and 6 (26%) developed distant metastases. The 3-year disease-free survival was 67%, and median overall survival was 54 months. CONCLUSIONS: Outcomes of this trial were satisfactory. Although the trial did not meet the predefined criteria of feasibility owing to the comparatively high rates of grade 3 dermatitis, numbers are comparable to existing data on cetuximab + radiation therapy.
引用
- Adeberg S, Akbaba S, Lang K, et al. The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019. PMID: 31586664. doi:10.1016/j.ijrobp.2019.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。